Pure Global AI
NCT06367959Recruiting

Health Benefits of Writing Therapy Among Asian American Cancer Survivors

M.D. Anderson Cancer CenterClinicalTrials.govbehavioral
Verified
Study focus
Disease/Condition
Cancer
Drug/Device/Intervention
Esays
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
M.D. Anderson Cancer Center
Location
Houston, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jul 27, 2023
End date
Aug 31, 2026
Enrollment
192 participants
Primary outcome

Primary Outcome Measure: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Summary

To learn more about participant experience as a Asian American immigrant breast cancer
 survivor and how writing about participant experiences may affect participant's health.

ICD-10 classifications
Carcinoid syndromeOther chemotherapyCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Prepuce
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06367959
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06367959 through Pure Global AI's free database. This phase not specified trial is sponsored by M.D. Anderson Cancer Center and is currently Recruiting. The study focuses on Cancer. Target enrollment is 192 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.